Dong Z, Luo J, Xu W
Research Laboratory of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang.
Zhonghua Zhong Liu Za Zhi. 1997 Jan;19(1):72-5.
To evaluate relationship between drug resistance of leukemia cells and prognosis.
The expression of multidrug resistance gene(mdr1) mRNA was measured in 85 patients with acute leukemia and in 20 normal controls by using reverse transcription polymerase chain reaction (RT-PCR).
The mdr1 positive rate in untreated group was 44.7%. The CR rate differed significantly between mdr1+ (23.9%) and mdr1-(88.5%)(P < 0.005). The mdr1 positive rate of refractory-relapsed group was higher than that in CR group (P < 0.001). The mdr1 mRNA expression level of refractory-relapsed group was higher than that in CR group. A gradually increasing level of mdr1 mRNA expression in CR patients indicated early relapse. The mdr1 positive rate in normal contral and long-term surviver patients was very low. The mdr1 expression was correlated with French-American-Birtish Cooperative Group (FAB) classification.
The mdr1 expression correlated with chemotherapeutic effect and prognosis. It is an unfavorable prognostic factor for patients with acute leukemia.
评估白血病细胞耐药性与预后之间的关系。
采用逆转录聚合酶链反应（RT-PCR）检测85例急性白血病患者及20例正常对照者多药耐药基因（mdr1）mRNA的表达。
未治疗组mdr1阳性率为44.7%。mdr1阳性组（23.9%）与mdr1阴性组（88.5%）的完全缓解（CR）率差异有统计学意义（P<0.005）。难治复发组mdr1阳性率高于CR组（P<0.001）。难治复发组mdr1 mRNA表达水平高于CR组。CR患者中mdr1 mRNA表达水平逐渐升高提示早期复发。正常对照者及长期生存患者mdr1阳性率极低。mdr1表达与法美英协作组（FAB）分型相关。
mdr1表达与化疗疗效及预后相关。它是急性白血病患者不良的预后因素。
